SCHEMBL10192804

SCHEMBL10192804

Cc1ccc(C(=O)C2=C(Cl)CCCC2=O)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.38
NPC1 O15118 5/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
RECQL P46063 1/20 0.37
PAX8 Q06710 1/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
GLA P06280 1/20 0.36
KMT2A Q03164 1/20 0.36
MCL1 Q07820 1/20 0.36
NFE2L2 Q16236 1/20 0.35
POLB P06746 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10192814 0.86 RAB9A (0.36) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL10192817 0.82 TP53 (0.40) RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL10192410 0.77 P2RX7 (0.41) L3MBTL1KDM4EALDH1A1HPGD
SCHEMBL10192413 0.74 HPGD (0.47) RAB9ANPC1KDM4EALDH1A1LMNA
SCHEMBL15133263 0.74 MAP2K1 (0.33) MAPTSMN1; SMN2L3MBTL1POLBTSHR
SCHEMBL10192426 0.74 RAB9A (0.47) RAB9ANPC1MAPTFLT1FLT4
SCHEMBL10192802 0.73 HTT (0.43) RAB9ASMN1; SMN2L3MBTL1ALDH1A1LMNA
SCHEMBL9190248 0.73 PTGS2 (0.45) RAB9AMAPTALDH1A1LMNAKMT2A
SCHEMBL10192813 0.73 KMT2A (0.46) RAB9ANPC1MAPTSMN1; SMN2RECQL
SCHEMBL286054 0.72 LMNA (0.50) RAB9ANPC1SMN1; SMN2FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595987-B1 NEW AMINOPYRAZOLOQUINAZOLINES BOEHRINGER INGELHEIM INT (DE) 2018-04-18 EP disclosed
US-8735386-B2 Aminopyrazoloquinazolines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-27 US disclosed
US-8735386-B2 Aminopyrazoloquinazolines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-05-27 US disclosed
US-20120238542-A1 AMINOPYRAZOLOQUINAZOLINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-20 US disclosed
US-20120238542-A1 AMINOPYRAZOLOQUINAZOLINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-20 US disclosed
WO-2012010704-A1 NEW AMINOPYRAZOLOQUINAZOLINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238542-A1 AMINOPYRAZOLOQUINAZOLINES CCNT1, CCNI, MKI67 RAB9A 1908/4885NPC1 685/4885MAPT 3841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.